ClinicalTrials.gg
Active, not recruitingNCT05492578RIVER-ADUpdated Oct 13, 2026

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

A Phase 2/3 interventional study of Amlitelimab and Topical corticosteroids in Dermatitis Atopic, sponsored by Sanofi. Active, not recruiting at 392 sites in 29 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment

Updated Oct 13, 202633 sites added31 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,856
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing amlitelimab in Dermatitis, Atopic — none open to participants now, 4 under way, 3 of them phase 3. amlitelimab · Dermatitis, Atopic.

Enrollment
Largest of 11
1,856 · median 589
Started
2022
the only one that year
Phase 2/3
Only one
of the 11
Registered
3rd of 11
by date
Lead sponsor
9 of 11
Sanofi

Among the 11 studies testing amlitelimab in Dermatitis, Atopic, this one has the largest enrollment, is the only one that started in 2022, is the only one in phase 2/3, and was the 3rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 11 studies testing amlitelimab in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About amlitelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing amlitelimab in Dermatitis, Atopic as a file.
02

Study summary

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis.

The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated participants with moderate to severe atopic dermatitis (AD) who have previously been enrolled in an amlitelimab clinical trial. All participants will have visits during the treatment period every 4 weeks. Responder participants rolling over from EFC17599 and EFC17600, and responder participants enrolling through screening from DRI17366 will be initiated into drug withdrawal (with no drug administration) at LTS17367 baseline visit to monitor durability of treatment response. If these responder participants relapse during LTS17367, they will have treatment restored. Non-responder participants rolling over from EFC17599 or EFC17600, and non-responder participants enrolling through screening from DRI17366 will have treatment administration from LTS17367 baseline. Participants rolling over from DRI17366, SFY17915 and INT18404 will also have treatment administration from LTS17367 baseline.

Remote visits with home dosing are allowed for the purpose of study drug administration, when applicable. In the case of remote visit with home dosing, the participant or a caregiver may administer study drug after appropriate training. Alternatively, if needed, and based on the investigator's judgement, home visits with healthcare professional assistance or on-site study drug administration visits can be performed. Where participants discontinue amlitelimab permanently during LTS17367, safety follow up will be performed for a minimum of 140 days from the last amlitelimab administration.

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participant must be at least 12 years of age inclusive at the time of signing the .
  • Participated in an amlitelimab clinical trial for moderate to severe AD and received study treatment, adequately completed the assessments required for the treatment period.

    • Have reached the rollover timepoint to LTS17367 at the last visit of the treatment period of their feeder study SFY17915, INT18404, EFC17599, or EFC17600
    • Participants in DRI17366 must only be enrolled from 1 of the following 3 groups:

      • The first group: participants at Week 24 in the DRI17336 study who have not achieved an ≥ Eczema Area and Skin Severity Index (EASI)-75 and are Investigator Global Assessment (IGA) ≥ 2.
      • The second group: participants entering LTS17367 between Week 28 and Week 52 of the feeder study, due to loss of clinical response in the part 2 of the feeder study. Timepoints for entering LTS17367 are Weeks 28, 32, 36, 40, 44, 48 or 52.
      • The third group: participants at Week 24 in DRI17366 who have been re-randomized and who subsequently complete the study to Week 52, enter safety follow-up and experience worsening of their AD during safety follow-up.
    • Participated in DRI17366 completing the previous study safety follow up (Week 68) and wish to re-initiate treatment with amlitelimab up to one year after the last visit
  • Complied with the previous clinical trial protocol to the satisfaction of the investigator
  • Body weight must be ≥25 kg
  • Provided signed informed assent/or consent and able to comply with the requirements of the protocol Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Developed a medical condition that would preclude participation as described in the section for permanent discontinuation of the feeder study or LTS17367 protocol
  • Known history of or suspected current significant , including history of invasive opportunistic infections or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration
  • History of solid organ or stem cell transplant
  • Any or history of malignancies prior to baseline (except for non-melanoma skin cancer that has been excised and completely cured for more than 5 years prior to baseline)
  • Participants positive for (HIV); participants with any of the following results at Screening (Visit 1) or at any point during the feeder study: presence of with or without HBV DNA PCR test, or presence of anti-HBc Ab or presence of anti-HBs Ab with positive HBV DNA PCR test; positive HCVAb confirmed by positive PCR test
  • History (within last 2 years prior to baseline) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • Participants with active TB, latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, non-TB mycobacterial infection, or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to screening
  • Participants with an indeterminate or a confirmed positive IGRA test are excluded from the study unless all of the following conditions are met:

    1. Have a history of prior documented completed chemoprophylaxis for latent TB infection (with a treatment regimen as per local guidelines), OR treated for active TB infection
    2. Have been in written form approved for participation in the present trial by a TB specialist who ruled out latent or active TB infection or other mycobacterial infection in the participant
    3. For whom review and approval from Sponsor have been granted are eligible
  • Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease
  • Skin co-morbidity that would adversely affect the ability to undertake AD assessments (e.g., psoriasis, tinea corporis, lupus erythematosus) as per Investigator's judgment
  • Any medical condition which, in the opinion of the Investigator may present an unreasonable risk to the study participant as a result of his/her participation in this clinical study, may make participant's participation unreliable, or may interfere with study assessments
  • In the Investigator's opinion, medical conditions related to prior AD medications that have not healed/fully recovered for more than 2 weeks before screening visit, including, but not limited to, conjunctivitis, keratitis, eosinophilic conditions, arthralgia, herpes zoster, thrombosis

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,856 participants (actual)

Study arms

  • Experimental
    Amlitelimab dose level 1

    Subcutaneous injection as per protocol

    Drug: Amlitelimab · Drug: Topical corticosteroids · Drug: Topical calcineurin inhibitors · Drug: Oral corticosteroids

  • Experimental
    Amlitelimab dose level 2

    Subcutaneous injection as per protocol

    Drug: Amlitelimab · Drug: Topical corticosteroids · Drug: Topical calcineurin inhibitors · Drug: Oral corticosteroids

Interventions

  • Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

    Also known as: SAR445229

  • Pharmaceutical form: Topical Route of administration: Topical

  • Pharmaceutical form: Topical Route of administration: Topical

  • DrugOral corticosteroids

    Pharmaceutical form: Oral Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Percentage of participants who experienced treatment-emergent adverse event (TEAE)

    Time frame: Baseline to Week 332

Secondary outcomes

  1. Percentage of participants who experienced treatment-emergent serious adverse events (SAEs)

    Time frame: Baseline to Week 332

  2. Percentage of participants who experienced treatment-emergent adverse events of special interest (AESI)

    Time frame: Baseline to Week 332

  3. Percentage of participants who experienced TEAE leading to treatment discontinuation

    Time frame: Baseline to Week 332

  4. Absolute change from DRI17366 baseline in EASI score at each LTS17367 visit in participants entering the study from DRI17366 Week 24

    EASI measures the severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: DRI17366 Baseline to Week 332

  5. Percent change from DRI17366 baseline in EASI score at each LTS17367 visit in participants entering the study from DRI17366 Week 24

    EASI measures the severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: DRI17366 Baseline to Week 332

  6. Proportion of participants with EASI50/EASI75/EASI90/EASI100 from DRI17366 baseline at each LTS17367 visit in participants entering the study from DRI17366 Week 24

    EASI measures the severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. EASI50: \>= 50% reduction in score from baseline; EASI75: \>= 75% reduction in score from baseline; EASI90: \>= 90% reduction in score from baseline; EASI100: \>= 100% reduction in score from baseline.

    Time frame: DRI17366 Baseline to Week 332

  7. Proportion of participants with a response of Validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) 0 or 1 at each LTS17367 visit in participants entering the study from DRI17366 Week 24

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  8. Proportion of participants with vIGA-AD score 0/1 in all participants entering the study [each LTS17367 visit]

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  9. Proportion of participants with vIGA-AD score 0 [each LTS17367 visit]

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  10. Proportion of participants with vIGA-AD score 0 or 1 with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting) at each LTS17367 visit

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  11. Time to first vIGA-AD 0/1 after LTS17367 enrollment in those participants who had not achieved vIGA-AD 0/1 by the time of LTS17367 enrollment

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  12. Absolute change from feeder study baseline in EASI score in all participants entering the study [each LTS17367 visit]

    EASI measures the severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: Baseline to Week 332

  13. Percent change from feeder study baseline in EASI score in all participants entering the study [each LTS17367 visit]

    EASI measures the severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: Baseline to Week 332

  14. Proportion of participants with EASI50/EASI75/EASI90 in all participants entering the study [each LTS17367 visit]

    EASI measures the severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. EASI50: \>= 50% reduction in score from baseline; EASI75: \>= 75% reduction in score from baseline; EASI90: \>= 90% reduction in score from baseline.

    Time frame: Baseline to Week 332

  15. Time to first EASI75/EASI90 in those participants who had not achieved it by the time of LTS17367 enrollment

    EASI measures the severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. EASI75: \>= 75% reduction in score from baseline; EASI90: \>= 90% reduction in score from baseline.

    Time frame: Baseline to Week 332

  16. Proportion of participants requiring topical treatment in all participants entering the study [each LTS17367 visit]

    Time frame: Baseline to Week 332

  17. Proportion of participants requiring rescue treatment [each LTS17367 visit]: all treatments in all participants entering the study

    Time frame: Baseline to Week 332

  18. Number of days on topical medication (per patient-year) in all participants entering the study

    Time frame: Baseline to Week 332

  19. Change from feeder study baseline atopic dermatitis control tool (ADCT) in all participants entering the study [each LTS17367 visit]

    ADCT is a six-item patient self-administered instrument designed and validated to assess atopic dermatitis (AD) control. The score ranges from 0-24 with higher scores indicate worsening disease control.

    Time frame: Baseline to Week 332

  20. Change from feeder study baseline in dermatology life quality index (DLQI/cDLQI) in all participants entering the study [each LTS17367 visit]

    The DLQI is a validated 10-item questionnaire to measure dermatology specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL. The children's DLQI (cDLQI) measures dermatology specific quality of life (QoL) in children patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 332

  21. Change from feeder study baseline in patient oriented eczema measure (POEM) in all participants entering the study [each LTS17367 visit]

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a scale ranging from 0 to 4 (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, 4 = all days). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline to Week 332

  22. Change from feeder study baseline in body surface area affected by AD (BSA-AD) [each LTS17367 visit]

    BSA-AD measured as percentage of body affected by AD.

    Time frame: Baseline to Week 332

  23. Time from enrollment in LTS17367 to first loss of vIGA-AD 0 in those participants who were vIGA-AD 0 at LTS17367 rollover from EFC17600 (ESTUARY) and EFC17599 (AQUA)

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  24. Time from enrollment in LTS17367 to first loss EASI75 in those participants who had reached EASI75 at LTS17367 rollover coming from EFC17600 (ESTUARY) and EFC17599 (AQUA)

    EASI measures the severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Total score ranges from 0 (minimum) to 72 (maximum), higher indicated greater severity of AD. EASI75: \>= 75% reduction in score from baseline.

    Time frame: Baseline to Week 332

  25. Time from enrollment in LTS17367 to first loss of vIGA-AD 0/1 in those participants who were vIGA-AD 0/1 at LTS17367 rollover from EFC17600 (ESTUARY) and EFC17599 (AQUA)

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  26. Time from LTS17367 baseline to re-treatment with amlitelimab in those participants who were vIGA-AD 0/1 at LTS17367 rollover from EFC17600 (ESTUARY) and EFC17599 (AQUA)

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  27. Time from last amlitelimab dose in feeder study to re-treatment with amlitelimab in those participants who were vIGA-AD 0/1 at LTS17367 rollover from EFC17600 (ESTUARY) and EFC17599 (AQUA)

    The vIGA-AD is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline to Week 332

  28. Serum amlitelimab concentration assessed at prespecified time points through the end of the study

    Serum amlitelimab concentration assessed at prespecified time points through the end of the study.

    Time frame: Baseline to Week 332

  29. Number of participants with anti-drug antibodies (ADAs) of amlitelimab at specified timepoints

    Time frame: Baseline to Week 332

07

Study locations

392 sites
  • Allervie Clinical Research - Birmingham- Site Number : 8401101
    Birmingham, Alabama 35209, United States
  • Cahaba Dermatology & Skin Health Center- Site Number : 8401066
    Birmingham, Alabama 35244, United States
  • Center for Dermatology and Plastic Surgery- Site Number : 8401119
    Scottsdale, Arizona 85260, United States
  • Scottsdale Clinical Trials- Site Number : 8401149
    Scottsdale, Arizona 85260, United States
  • Eclipse Clinical Research- Site Number : 8401158
    Tucson, Arizona 85745, United States
  • Arkansas Research Trials- Site Number : 8401244
    North Little Rock, Arkansas 72217, United States
  • Orange County Clinical Trials- Site Number : 8401271
    Anaheim, California 92801, United States
  • Encino Research Center- Site Number : 8401042
    Encino, California 91436, United States
  • First OC Dermatology- Site Number : 8401025
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research- Site Number : 8401018
    Fremont, California 94538, United States
  • Marvel Clinical Research- Site Number : 8401102
    Huntington Beach, California 92647, United States
  • Sunwise Clinical Research - Lafayette- Site Number : 8401022
    Lafayette, California 94549, United States
  • Antelope Valley Clinical Trials- Site Number : 8401099
    Lancaster, California 93534, United States
  • Torrance Clinical Research - Narbonne Avenue- Site Number : 8401027
    Lomita, California 90717, United States
  • Long Beach Clinical Trials- Site Number : 8401188
    Long Beach, California 90806, United States
  • Dermatology Research Associates- Site Number : 8401092
    Los Angeles, California 90045, United States
  • LA Universal Research Center- Site Number : 8401064
    Los Angeles, California 90057, United States
  • University Dermatology Trials- Site Number : 8401339
    Newport Beach, California 92660, United States
  • Cura Clinical Research - Oxnard- Site Number : 8401142
    Oxnard, California 93030, United States
  • Southern California Dermatology- Site Number : 8401043
    Santa Ana, California 92701, United States
  • Clinical Science Institute- Site Number : 8401028
    Santa Monica, California 90404, United States
  • Paradigm Clinical Research - Wheat Ridge- Site Number : 8401245
    Wheat Ridge, Colorado 80033, United States
  • UConn Health - Farmington- Site Number : 8401115
    Farmington, Connecticut 06030, United States
  • Encore Medical Research of Boynton Beach- Site Number : 8401030
    Boynton Beach, Florida 33436, United States
  • Pediatric Skin Research- Site Number : 8401198
    Coral Gables, Florida 33146, United States
  • St. Jude Clinical Research- Site Number : 8401287
    Doral, Florida 33172, United States
  • Alliance for Multispeciality Research - Fort Myers- Site Number : 8401111
    Fort Myers, Florida 33912, United States
  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286
    Fort Myers, Florida 33919, United States
  • Direct Helpers Research Center- Site Number : 8401056
    Hialeah, Florida 33012, United States
  • Doral Medical Research - Hialeah- Site Number : 8401094
    Hialeah, Florida 33016, United States
  • Apex Clinical Research - Jacksonville- Site Number : 8401332
    Jacksonville, Florida 32256, United States
  • Clever Medical Research- Site Number : 8401160
    Miami, Florida 33126, United States
  • Miami Dermatology and Laser Research- Site Number : 8401086
    Miami, Florida 33133, United States
  • Medical Research Center of Miami II- Site Number : 8401019
    Miami, Florida 33134, United States
  • Acevedo Clinical Research Associates- Site Number : 8401088
    Miami, Florida 33142, United States
  • Future Care Solution - Miami- Site Number : 8401144
    Miami, Florida 33142, United States
  • Sanchez Clinical Research- Site Number : 8401095
    Miami, Florida 33157, United States
  • Florida International Research Center- Site Number : 8401091
    Miami, Florida 33173, United States
  • Savin Medical Group - Miami Lakes- Site Number : 8401085
    Miami Lakes, Florida 33014, United States
  • Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8401109
    Miami Lakes, Florida 33016, United States
  • K2 South Orlando - South Orange Avenue- Site Number : 8401268
    Orlando, Florida 32806, United States
  • Nuline Clinical Trial Center- Site Number : 8401161
    Pompano Beach, Florida 33060, United States
  • Global Clinical Professionals (GCP)- Site Number : 8401045
    St. Petersburg, Florida 33714, United States
  • Clinical Research Trials of Florida- Site Number : 8401023
    Tampa, Florida 33607, United States
  • Alliance Clinical Research of Tampa- Site Number : 8401013
    Tampa, Florida 33615, United States
  • Cleaver Medical Group- Site Number : 8401138
    Dawsonville, Georgia 30534, United States
  • First Georgia Physician Group- Site Number : 8401190
    Fayetteville, Georgia 30214, United States
  • Dermatologic Surgery Specialists- Site Number : 8401034
    Macon, Georgia 31217, United States
  • Aeroallergy Research Laboratory- Site Number : 8401004
    Savannah, Georgia 31406, United States
  • Javara Research - Thomasville- Site Number : 8401189
    Thomasville, Georgia 31792, United States
  • Rophe Adult & Pediatric Medicine- Site Number : 8401289
    Union City, Georgia 30291, United States
  • Northwestern University Feinberg School of Medicine- Site Number : 8401285
    Chicago, Illinois 60611, United States
  • Northwestern University- Site Number : 8401038
    Chicago, Illinois 60611, United States
  • Dawes Fretzin Clinical Research- Site Number : 8401015
    Indianapolis, Indiana 46256, United States
  • Equity Medical - Bowling Green- Site Number : 8401296
    Bowling Green, Kentucky 42104, United States
  • Skin Sciences- Site Number : 8401039
    Louisville, Kentucky 40217, United States
  • Velocity Clinical Research at The Dermatology Clinic - Baton Rouge- Site Number : 8401072
    Baton Rouge, Louisiana 70809, United States
  • MedPharmics - Covington- Site Number : 8401137
    Covington, Louisiana 70433, United States
  • BRCR Global Gretna- Site Number : 8401243
    Gretna, Louisiana 70053, United States
  • Velocity Clinical Research - Lafayette- Site Number : 8401152
    Lafayette, Louisiana 70508, United States
  • MetroBoston Clinical Partners - Brighton- Site Number : 8401128
    Brighton, Massachusetts 02135, United States
  • Henry Ford Hospital- Site Number : 8401044
    Detroit, Michigan 48202, United States
  • Revival Research Institute - Troy- Site Number : 8401012
    Troy, Michigan 48084, United States
  • Oakland Medical Center- Site Number : 8401116
    Troy, Michigan 48085, United States
  • Allergy Immunology Assoc Ann Arbor- Site Number : 8401078
    Ypsilanti, Michigan 48197, United States
  • SKY Integrative Medical Center/SKYCRNG- Site Number : 8401058
    Ridgeland, Mississippi 39157, United States
  • Skin Specialists- Site Number : 8401068
    Omaha, Nebraska 68144, United States
  • Pulmonology Group - Henderson- Site Number : 8401169
    Henderson, Nevada 89052, United States
  • Jubilee Clinical Research- Site Number : 8401054
    Las Vegas, Nevada 89106, United States
  • Schweiger Dermatology Group - East Windsor- Site Number : 8401338
    East Windsor, New Jersey 08520, United States
  • Care Access - Hoboken- Site Number : 8401132
    Hoboken, New Jersey 07030, United States
  • The University of New Mexico- Site Number : 8401263
    Albuquerque, New Mexico 87106, United States
  • Sadick Research Group - New York - Park Avenue- Site Number : 8401050
    New York, New York 10075, United States
  • OptiSkin- Site Number : 8401163
    New York, New York 10128, United States
  • Skin Search Rochester- Site Number : 8401216
    Rochester, New York 14623, United States
  • Equity Medical (LLC)- Site Number : 8401239
    The Bronx, New York 10455, United States
  • AXIS Clinicals - Fargo- Site Number : 8401196
    Fargo, North Dakota 58103, United States
  • Cincinnati Children's Hospital Medical Center- Site Number : 8401279
    Cincinnati, Ohio 45229, United States
  • Apex Clinical Research Center- Site Number : 8401237
    Mayfield Heights, Ohio 44124, United States
  • Oregon Health & Science University (OHSU)- Site Number : 8401247
    Portland, Oregon 97239, United States
  • Best Skin Research - Camp Hill- Site Number : 8401031
    Camp Hill, Pennsylvania 17011, United States
  • Paddington Testing Company- Site Number : 8401041
    Philadelphia, Pennsylvania 19103, United States
  • Clinical Research of Philadelphia- Site Number : 8401193
    Philadelphia, Pennsylvania 19114, United States
  • Dermatology Associates of Plymouth Meeting- Site Number : 8401147
    Plymouth Meeting, Pennsylvania 19462, United States
  • Velocity Clinical Research - Columbia- Site Number : 8401176
    Columbia, South Carolina 29204, United States
  • Columbia Dermatology & Aesthetics- Site Number : 8401166
    Columbia, South Carolina 29212, United States
  • Health Concepts- Site Number : 8401059
    Rapid City, South Dakota 57702, United States
  • Arlington Research Center- Site Number : 8401248
    Arlington, Texas 76011, United States
  • Dermatology Treatment and Research Center- Site Number : 8401164
    Dallas, Texas 75230, United States
  • Modern Research Associates- Site Number : 8401093
    Dallas, Texas 75231, United States
  • Derm Texas- Site Number : 8401217
    Dallas, Texas 75235, United States
  • Reveal Research Institute - Dallas- Site Number : 8401219
    Dallas, Texas 75235, United States
  • Prolato Clinical Research Center- Site Number : 8401209
    Houston, Texas 77054, United States
  • SMS Clinical Research- Site Number : 8401182
    Mesquite, Texas 75149, United States
  • Synapse Clinical Research - Missouri City- Site Number : 8401148
    Missouri City, Texas 77459, United States
  • Stryde Research - Epiphany Dermatology- Site Number : 8401185
    Southlake, Texas 76092, United States
  • Complete Dermatology - Site Number : 8401061
    Sugar Land, Texas 77479, United States
  • Tanner Clinic - Layton Antelope A- Site Number : 8401151
    Layton, Utah 84041, United States
  • Care Access Research - Arlington- Site Number : 8401134
    Arlington, Virginia 22206, United States
  • Virginia Dermatology & Skin Cancer Center- Site Number : 8401047
    Norfolk, Virginia 23502, United States

Showing the first 100 of 392 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Jan 2029, 77 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2022
First posted
Aug 8, 2022
StartActual
Aug 22, 2022
Primary completionEst.
Jan 22, 2029
CompletionEst.
Jan 22, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
33 sites added, 31 sites removed
Show 33 added (12 United States, 6 Poland, 5 Spain, 3 Japan, 2 Canada, 1 Australia, 1 Brazil, 1 France, 1 Germany, 1 South Africa)
  • Sunwise Clinical Research - Lafayette- Site Number : 8401022 · Lafayette, United States
  • Dermatology Research Associates- Site Number : 8401092 · Los Angeles, United States
  • Miami Dermatology and Laser Research- Site Number : 8401086 · Miami, United States
  • Dermatologic Surgery Specialists- Site Number : 8401034 · Macon, United States
  • Northwestern University Feinberg School of Medicine- Site Number : 8401285 · Chicago, United States
  • Allergy Immunology Assoc Ann Arbor- Site Number : 8401078 · Ypsilanti, United States
  • SKY Integrative Medical Center/SKYCRNG- Site Number : 8401058 · Ridgeland, United States
  • Equity Medical (LLC)- Site Number : 8401239 · The Bronx, United States
  • Health Concepts- Site Number : 8401059 · Rapid City, United States
  • Derm Texas- Site Number : 8401217 · Dallas, United States
  • Complete Dermatology - Site Number : 8401061 · Sugar Land, United States
  • Care Access Research - Arlington- Site Number : 8401134 · Arlington, United States
  • Investigational Site Number : 0360007 · Greenslopes, Australia
  • Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760022 · Curitiba, Brazil
  • Investigational Site Number : 1240035 · Toronto, Canada
  • Investigational Site Number : 1240028 · Regina, Canada
  • Investigational Site Number : 2500004 · Créteil, France
  • Investigational Site Number : 2760022 · Frankfurt, Germany
  • Investigational Site Number : 3923115 · Chūō, Japan
  • Investigational Site Number : 3920006 · Kobe, Japan
  • Investigational Site Number : 3920008 · Sapporo, Japan
  • Investigational Site Number : 6160010 · Tarnów, Poland
  • Investigational Site Number : 6160004 · Lublin, Poland
  • Investigational Site Number : 6160009 · Warsaw, Poland
  • Investigational Site Number : 6160007 · Warsaw, Poland
  • Investigational Site Number : 6160003 · Katowice, Poland
  • Investigational Site Number : 6162407 · Krakow, Poland
  • Investigational Site Number : 7100009 · Cape Town, South Africa
  • Investigational Site Number : 7240020 · Seville, Spain
  • Investigational Site Number : 7240010 · Esplugues de Llobregat, Spain
  • …and 3 more on the registry record
Show 31 removed
  • Sunwise Clinical Research- Site Number : 8401022 · Lafayette, United States
  • Dermatology Research Associates - Los Angeles- Site Number : 8401092 · Los Angeles, United States
  • Miami Dermatology and Laser Research - Miami - South Miami Avenue- Site Number : 8401086 · Miami, United States
  • Allergy & Immunology Associates of Ann Arbor- Site Number : 8401078 · Ypsilanti, United States
  • SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058 · Ridgeland, United States
  • Equity Medical- Site Number : 8401239 · New York, United States
  • Health Concepts - Site Number : 8401059 · Rapid City, United States
  • Complete Dermatology - Sugar Land- Site Number : 8401061 · Sugar Land, United States
  • Care Access - Arlington- Site Number : 8401134 · Arlington, United States
  • Investigational Site Number : 0360007 · Woolloongabba, Australia
  • Investigational Site Number: 1240035 · Toronto, Canada
  • Investigational Site Number: 1240028 · Regina, Canada
  • Investigational Site Number : 2080001 · Aarhus, Denmark
  • Investigational Site Number : 3920008 · Sapporo, Japan
  • Investigational Site Number : 3920006 · Kobe, Japan
  • Investigational Site Number : 3923115 · Chūō, Japan
  • Investigational Site Number : 3923113 · Yokohama, Japan
  • Investigational Site Number : 6162407 · Krakow, Poland
  • Investigational Site Number: 6160010 · Tarnów, Poland
  • Investigational Site Number: 6160004 · Lublin, Poland
  • Investigational Site Number : 6162415 · Lodz, Poland
  • Investigational Site Number : 6162416 · Lodz, Poland
  • Investigational Site Number: 6160009 · Warsaw, Poland
  • Investigational Site Number: 6160007 · Warsaw, Poland
  • Investigational Site Number : 6162419 · Bialystok, Poland
  • Investigational Site Number: 6160003 · Katowice, Poland
  • Investigational Site Number: 7100009 · Cape Town, South Africa
  • Investigational Site Number : 7240012 · Las Palmas de Gran Canaria, Spain
  • Investigational Site Number : 7240020 · Seville, Spain
  • Investigational Site Number : 7240023 · Burjassot, Spain
  • …and 1 more on the registry record
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    33 sites added, 31 sites removed
    Show 33 added (12 United States, 6 Poland, 5 Spain, 3 Japan, 2 Canada, 1 Australia, 1 Brazil, 1 France, 1 Germany, 1 South Africa)
    • Sunwise Clinical Research - Lafayette- Site Number : 8401022 · Lafayette, United States
    • Dermatology Research Associates- Site Number : 8401092 · Los Angeles, United States
    • Miami Dermatology and Laser Research- Site Number : 8401086 · Miami, United States
    • Dermatologic Surgery Specialists- Site Number : 8401034 · Macon, United States
    • Northwestern University Feinberg School of Medicine- Site Number : 8401285 · Chicago, United States
    • Allergy Immunology Assoc Ann Arbor- Site Number : 8401078 · Ypsilanti, United States
    • SKY Integrative Medical Center/SKYCRNG- Site Number : 8401058 · Ridgeland, United States
    • Equity Medical (LLC)- Site Number : 8401239 · The Bronx, United States
    • Health Concepts- Site Number : 8401059 · Rapid City, United States
    • Derm Texas- Site Number : 8401217 · Dallas, United States
    • Complete Dermatology - Site Number : 8401061 · Sugar Land, United States
    • Care Access Research - Arlington- Site Number : 8401134 · Arlington, United States
    • Investigational Site Number : 0360007 · Greenslopes, Australia
    • Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760022 · Curitiba, Brazil
    • Investigational Site Number : 1240035 · Toronto, Canada
    • Investigational Site Number : 1240028 · Regina, Canada
    • Investigational Site Number : 2500004 · Créteil, France
    • Investigational Site Number : 2760022 · Frankfurt, Germany
    • Investigational Site Number : 3923115 · Chūō, Japan
    • Investigational Site Number : 3920006 · Kobe, Japan
    • Investigational Site Number : 3920008 · Sapporo, Japan
    • Investigational Site Number : 6160010 · Tarnów, Poland
    • Investigational Site Number : 6160004 · Lublin, Poland
    • Investigational Site Number : 6160009 · Warsaw, Poland
    • Investigational Site Number : 6160007 · Warsaw, Poland
    • Investigational Site Number : 6160003 · Katowice, Poland
    • Investigational Site Number : 6162407 · Krakow, Poland
    • Investigational Site Number : 7100009 · Cape Town, South Africa
    • Investigational Site Number : 7240020 · Seville, Spain
    • Investigational Site Number : 7240010 · Esplugues de Llobregat, Spain
    • …and 3 more on the registry record
    Show 31 removed
    • Sunwise Clinical Research- Site Number : 8401022 · Lafayette, United States
    • Dermatology Research Associates - Los Angeles- Site Number : 8401092 · Los Angeles, United States
    • Miami Dermatology and Laser Research - Miami - South Miami Avenue- Site Number : 8401086 · Miami, United States
    • Allergy & Immunology Associates of Ann Arbor- Site Number : 8401078 · Ypsilanti, United States
    • SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058 · Ridgeland, United States
    • Equity Medical- Site Number : 8401239 · New York, United States
    • Health Concepts - Site Number : 8401059 · Rapid City, United States
    • Complete Dermatology - Sugar Land- Site Number : 8401061 · Sugar Land, United States
    • Care Access - Arlington- Site Number : 8401134 · Arlington, United States
    • Investigational Site Number : 0360007 · Woolloongabba, Australia
    • Investigational Site Number: 1240035 · Toronto, Canada
    • Investigational Site Number: 1240028 · Regina, Canada
    • Investigational Site Number : 2080001 · Aarhus, Denmark
    • Investigational Site Number : 3920008 · Sapporo, Japan
    • Investigational Site Number : 3920006 · Kobe, Japan
    • Investigational Site Number : 3923115 · Chūō, Japan
    • Investigational Site Number : 3923113 · Yokohama, Japan
    • Investigational Site Number : 6162407 · Krakow, Poland
    • Investigational Site Number: 6160010 · Tarnów, Poland
    • Investigational Site Number: 6160004 · Lublin, Poland
    • Investigational Site Number : 6162415 · Lodz, Poland
    • Investigational Site Number : 6162416 · Lodz, Poland
    • Investigational Site Number: 6160009 · Warsaw, Poland
    • Investigational Site Number: 6160007 · Warsaw, Poland
    • Investigational Site Number : 6162419 · Bialystok, Poland
    • Investigational Site Number: 6160003 · Katowice, Poland
    • Investigational Site Number: 7100009 · Cape Town, South Africa
    • Investigational Site Number : 7240012 · Las Palmas de Gran Canaria, Spain
    • Investigational Site Number : 7240020 · Seville, Spain
    • Investigational Site Number : 7240023 · Burjassot, Spain
    • …and 1 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05492578
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 8, 2022
Start date
Aug 22, 2022
Primary completion
Jan 22, 2029 (estimated)
Completion
Jan 22, 2029 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion